References
1.
Jensen RT, Cadiot G, Brandi ML, et al: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
2.
Falconi M, Bartsch DK, Eriksson B, et al: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-134.
3.
Pavel M, Baudin E, Couvelard A, et al: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.
4.
Jensen RT, Berna MJ, Bingham MD, et al: Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008;113(7 suppl):1807-1843.
5.
Ito T, Igarashi H, Uehara H, et al: Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92:135-181.
6.
Levy-Bohbot N, Merle C, Goudet P, et al: Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004;28:1075-1081.
7.
Thakker RV, Newey PJ, Walls GV, et al: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011.
8.
Yao JC, Hassan M, Phan A, et al: One hundred years after ‘carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
9.
Capelli P, Fassan M, Scarpa A: Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:705-717.
10.
Ito T, Igarashi H, Nakamura K, et al: Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015;50:58-64.
11.
Cho MY, Kim JM, Sohn JH, et al: Current Trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012;44:157-165.
12.
Tsai HJ, Wu CC, Tsai CR, et al: The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013;8:e62487.
13.
Scherubl H, Streller B, Stabenow R, et al: Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 2013;19:9012-9019.
14.
Halfdanarson TR, Rabe KG, Rubin J, et al: Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;10:1727-1733.
15.
Sharma J, Duque M, Saif MW: Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therap Adv Gastroenterol 2013;6:474-490.
16.
Lee LC, Grant CS, Salomao DR, et al: Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 2012;152:965-974.
17.
Ito T, Igarashi H, Jensen RT: Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 2012;26:737-753.
18.
Kamp K, Feelders RA, van Adrichem RC, et al: Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab 2014;99:3060-3069.
19.
Garbrecht N, Anlauf M, Schmitt A, et al: Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008;15:229-241.
20.
Berna MJ, Hoffmann KM, Serrano J, et al: Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2,229 cases from the literature. Medicine (Baltimore) 2006;85:295-330.
21.
Berna MJ, Hoffmann KM, Long SH, et al: Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006;85:331-364.
22.
Ito T, Igarashi H, Jensen RT: Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013;29:650-661.
23.
Rehfeld JF, Federspiel B, Bardram L: A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med 2013;368:1165-1166.
24.
Rehfeld JF, Bardram L, Hilsted L, et al: Pitfalls in diagnostic gastrin measurements. Clin Chem 2012;58:831-836.
25.
Rehfeld JF, Gingras MH, Bardram L, et al: The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140:1444-1453.
26.
Poultsides GA, Huang LC, Chen Y, et al: Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol 2012;19:2295-2303.
27.
Panzuto F, Merola E, Rinzivillo M, et al: Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 2014;43:212-218.
28.
Panzuto F, Boninsegna L, Fazio N, et al: Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372-2377.
29.
Boninsegna L, Panzuto F, Partelli S, et al: Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012;48:1608-1615.
30.
Hashim YM, Trinkaus KM, Linehan DC, et al: Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 2014;259:197-203.
31.
Partelli S, Gaujoux S, Boninsegna L, et al: Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg 2013;148:932-939.
32.
Han X, Xu X, Jin D, et al: Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas 2014;43:526-531.
33.
Ricci C, Casadei R, Taffurelli G, et al: The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. Pancreatology 2013;13:589-593.
34.
Casadei R, Ricci C, Tomassetti P, et al: Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas. ISRN Surg 2012;2012:1-5.
35.
Parekh JR, Wang SC, Bergsland EK, et al: Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 2012;41:840-844.
36.
Tsutsumi K, Ohtsuka T, Mori Y, et al: Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol 2012;47:678-685.
37.
Crippa S, Partelli S, Zamboni G, et al: Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery 2014;155:145-153.
38.
Birnbaum DJ, Gaujoux S, Cherif R, et al: Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery 2014;155:13-21.
39.
Rindi G, Petrone G, Inzani F: The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol 2014;25:186-192.
40.
Klimstra DS: Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol 2013;40:23-36.
41.
Yang M, Tian BL, Zhang Y, et al: Evaluation of the world health organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. Pancreas 2014;43:1003-1008.
42.
Wong J, Fulp WJ, Strosberg JR, et al: Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg 2014;208:775-780.
43.
Morin E, Cheng S, Mete O, et al: Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Med 2013;2:701-711.
44.
Liu TC, Hamilton N, Hawkins W, et al: Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2013;37:853-859.
45.
Marinoni I, Kurrer AS, Vassella E, et al: Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014;146:453-460.
46.
Ito T, Igarashi H, Uehara H, et al: Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacotherapy 2013;14:307-321.
47.
Goudet P, Murat A, Binquet C, et al: Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010;34:249-255.
48.
Gibril F, Chen Y-J, Schrump DS, et al: Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-1081.
49.
Goudet P, Murat A, Cardot-Bauters C, et al: Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009;33:1197-1207.
50.
Wilson SD, Doffek KM, Krzywda EA, et al: Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? Surgery 2011;150:1129-1135.
51.
Toaiari M, Davi MV, Dalle Carbonare L, et al: Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. J Endocrinol Invest 2013;36:753-758.
52.
Iida K, Ohara T, Hino Y, et al: Glucose-responsive insulinoma in a patient with postprandial hypoglycemia in the morning. Intern Med 2010;49:2123-2127.
53.
Del Sindaco P, Casucci G, Pampanelli S, et al: Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotally gastrectomized patient. Eur J Endocrinol 1997;136:96-99.
54.
Ito T, Cadiot G, Jensen RT: Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol 2012;18:5495-5503.
55.
Poitras P, Gingras MH, Rehfeld JF: The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012;10:199-202.
56.
Metz DC: Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2012;10:126-130.
57.
Jensen RT, Niederle B, Mitry E, et al: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-182.
58.
Poitras P, Gingras MH, Rehfeld JF: Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome: to do or not to do? Pancreas 2013;42:903-904.
59.
Shibata C, Kakyo M, Kinouchi M, et al: Criteria for the glucagon provocative test in the diagnosis of gastrinoma. Surg Today 2013;43:1281-1285.
60.
Shah P, Singh MH, Yang YX, et al: Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas 2013;42:932-936.
61.
Ito T, Igarashi H, Jensen RT: Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012;41:505-507.
62.
Kanakis G, Kaltsas G: Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012;26:791-802.
63.
Rehfeld JF, Bardram L, Hilsted L, et al: An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. Biomark Med 2014;8:571-580.
64.
Roy PK, Venzon DJ, Feigenbaum KM, et al: Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001;80:189-222.
65.
Yamazaki M, Suzuki S, Kosugi S, et al: Delay in the diagnosis of multiple endocrine neoplasia type 1: typical symptoms are frequently overlooked. Endocr J 2012;59:797-807.
66.
de Laat JM, Tham E, Pieterman CR, et al: Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors. Eur J Endocrinol 2012;167:181-187.
67.
Sakurai A, Yamazaki M, Suzuki S, et al: Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1: analysis of the database of the MEN Consortium of Japan. Endocr J 2012;59:859-866.
68.
Gibril F, Schumann M, Pace A, et al: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004;83:43-83.
69.
Goncalves TD, Toledo RA, Sekiya T, et al: Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life. J Clin Endocrinol Metab 2014;99:E89-E96.
70.
Agin A, Charrie A, Chikh K, et al: Fast test: clinical practice and interpretation. Ann Endocrinol (Paris) 2013;74:174-184.
71.
Cryer PE, Axelrod L, Grossman AB, et al: Diagnostic accuracy of an ‘amended' insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med 2013;158:500-501.
72.
Buffet A, Vezzosi D, Maiza JC, et al: Increased plasma beta-hydroxybutyrate levels during the fasting test in patients with endogenous hyperinsulinaemic hypoglycaemia. Eur J Endocrinol 2013;169:91-97.
73.
Guettier JM, Lungu A, Goodling A, et al: The role of proinsulin and insulin in the diagnosis of insulinoma: a critical evaluation of the Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4752-4758.
74.
De Leon DD, Stanley CA: Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia. Best Pract Res Clin Endocrinol Metab 2013;27:763-769.
75.
Nauck MA, Meier JJ: Diagnostic accuracy of an ‘amended' insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med 2012;157:767-775.
76.
Cryer PE, Axelrod L, Grossman AB, et al: Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009;94:709-728.
77.
Okabayashi T, Shima Y, Sumiyoshi T, et al: Diagnosis and management of insulinoma. World J Gastroenterol 2013;19:829-837.
78.
Qiao XW, Qiu L, Chen YJ, et al: Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64.
79.
Modlin IM, Gustafsson BI, Moss SF, et al: Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427-2443.
80.
Sharma P, Arora S, Dhull VS, et al: Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom Imaging 2015;40:299-309.
81.
Sharma P, Arora S, Mukherjee A, et al: Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Clin Nucl Med 2014;39:37-43.
82.
Sharma P, Naswa N, Kc SS, et al: Comparison of the prognostic values of Ga-DOTANOC PET/CT and F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2014;41:2194-2202.
83.
Treglia G, Castaldi P, Rindi G, et al: Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-87.
84.
Rufini V, Baum RP, Castaldi P, et al: Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 2012;37:1004-1020.
85.
Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, et al: Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013;40:897-907.
86.
Etchebehere EC, de Oliveira SA, Gumz B, et al: 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 2014;55:1598-1604.
87.
Wild D, Bomanji JB, Benkert P, et al: Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364-372.
88.
Ambrosini V, Campana D, Bodei L, et al: 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-673.
89.
Naji M, Al-Nahhas A: (6)(8)Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging 2012;39(suppl 1):S61-S67.
90.
Sharma P, Arora S, Karunanithi S, et al: Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-Octreotide for localisation of clinically and biochemically suspected insulinoma. Q J Nucl Med Mol Imaging 2016;60:69-76.
91.
Sundin A: Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012;26:803-818.
92.
Naswa N, Sharma P, Soundararajan R, et al: Diagnostic performance of somatostatin receptor PET/CT using (68)Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 2013;38:552-560.
93.
Ilhan H, Fendler WP, Cyran CC, et al: Impact of Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol 2015;22:164-171.
94.
Bartsch DK, Waldmann J, Fendrich V, et al: Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg 2012;99:1234-1240.
95.
Lopez CL, Falconi M, Waldmann J, et al: Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg 2013;257:308-314.
96.
Dickson PV, Rich TA, Xing Y, et al: Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 2011;150:1143-1152.
97.
Ogawa S, Wada M, Fukushima M, et al: Case of primary hepatic gastrinoma: diagnostic usefulness of the selective arterial calcium injection test. Hepatol Res 2015;45:823-826.
98.
Naoe H, Iwasaki H, Kawasaki T, et al: Primary hepatic gastrinoma as an unusual manifestation of Zollinger-Ellison syndrome. Case Rep Gastroenterol 2012;6:590-595.
99.
Lu X, Aoun E, Morrissey S: Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. BMJ Case Rep 2012;2012:4.
100.
Tonelli F, Giudici F, Nesi G, et al: Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. World J Gastroenterol 2013;19:8312-8320.
101.
Bartsch DK, Albers M, Knoop R, et al: Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. Neuroendocrinology 2013;98:290-298.
102.
Lewis MA, Thompson GB, Young WF Jr: Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 2012;36:1375-1381.
103.
Naswa N, Sharma P, Kumar A, et al: 68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med 2012;37:245-251.
104.
Grozinsky-Glasberg S, Barak D, Fraenkel M, et al: Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011;117:1377-1385.
105.
Frilling A, Sotiropoulos GC, Radtke A, et al: The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850-856.
106.
Binderup T, Knigge U, Loft A, et al: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-985.
107.
Barbe C, Murat A, Dupas B, et al: Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 2012;44:228-234.
108.
Semelka RC, Custodio CM, Cem Balci N, et al: Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11:141-148.
109.
Foti G, Boninsegna L, Falconi M, et al: Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI. Radiol Med 2013;118:1082-1101.
110.
Kann PH, Kann B, Fassbender WJ, et al: Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006;114:361-365.
111.
Kann PH, Balakina E, Ivan D, et al: Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006;13:1195-1202.
112.
Tseng LM, Chen JY, Won JG, et al: The role of intra-arterial calcium stimulation test with hepatic venous sampling (IACS) in the management of occult insulinomas. Ann Surg Oncol 2007;14:2121-2127.
113.
Baba Y, Hayashi S, Senokuchi T, et al: Which indexes are appropriate among those derived from selective arterial calcium stimulation and venous sampling (ASVS) for diagnosing pancreatic insulinomas? Evaluation using receiver operating characteristic analyses. Pancreas 2011;40:308-310.
114.
Sowa-Staszczak A, Pach D, Mikolajczak R, et al: Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013;40:524-531.
115.
Cases AI, Ohtsuka T, Fujino M, et al: Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors. Pancreas 2014;43:1-6.
116.
Eriksson O, Velikyan I, Selvaraju RK, et al: Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab 2014;99:1519-1524.
117.
Christ E, Wild D, Forrer F, et al: Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398-4405.
118.
Braatvedt G, Jennison E, Holdaway IM: Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin. Clin Endocrinol (Oxf) 2014;80:80-84.
119.
Morganstein DL, Lewis DH, Jackson J, et al: The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol 2009;19:2467-2473.
120.
Giudici F, Nesi G, Brandi ML, et al: Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas 2012;41:547-553.
121.
Kloppel G: Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011;18(suppl 1):S1-S16.
122.
Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Kloppel G, Komminoth P, Solcia E: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, Carneiro F, Hruban RH, Theise N (eds): WHO Classification of Tumors of the Digestive System. Lyon, IARC Press, 2010, pp 13-14.
123.
Strosberg JR, Cheema A, Weber J, et al: Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011;29:3044-3049.
124.
Oberg K: The genetics of neuroendocrine tumors. Semin Oncol 2013;40:37-44.
125.
Martin-Perez E, Capdevila J, Castellano D, et al: Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology 2013;98:156-168.
126.
Rindi G, Falconi M, Klersy C, et al: TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012;104:764-777.
127.
Chan JA, Kulke MH: New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12:136-148.
128.
Ito T, Igarashi H, Jensen RT: Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012;47:941-960.
129.
Leung R, Lang B, Wong H, et al: Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Anticancer Agents Med Chem 2013;13:382-388.
130.
Fazio N, Scarpa A, Falconi M: Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. Curr Med Chem 2014;21:1017-1025.
131.
Scarpa A, Mantovani W, Capelli P, et al: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-833.
132.
Oberg K, Knigge U, Kwekkeboom D, et al: Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7):vii124-vii130.
133.
Krampitz GW, Norton JA, Poultsides GA, et al: Lymph nodes and survival in duodenal and pancreatic neuroendocrine tumors. Arch Surg 2012;147:820-827.
134.
Cao Y, Gao Z, Li L, et al: Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 2013;4:2810.
135.
Zhang L, Lohse CM, Dao LN, et al: Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol 2011;42:324-331.
136.
Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-1203.
137.
de Wilde RF, Edil BH, Hruban RH, et al: Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;9:199-208.
138.
Lee HS, Chen M, Kim JH, et al: Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Int J Cancer 2014;135:128-137.
139.
Agarwal SK, Mateo CM, Marx SJ: Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009;94:1826-1834.
140.
Thakker RV: Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014;386:2-15.
141.
Larghi A, Capurso G, Carnuccio A, et al: Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc 2012;76:570-577.
142.
Schmitt AM, Riniker F, Anlauf M, et al: Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008;32:420-425.
143.
Sangoi AR, Ohgami RS, Pai RK, et al: PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol 2011;24:412-424.
144.
Norton JA, Fraker DL, Alexander HR, et al: Value of surgery in patients with negative imaging and sporadic zollinger-ellison syndrome. Ann Surg 2012;256:509-517.
145.
Atema JJ, Amri R, Busch OR, et al: Surgical treatment of gastrinomas: a single-centre experience. HPB (Oxford) 2012;14:833-838.
146.
Maire F, Sauvanet A, Couvelard A, et al: Recurrence after surgical resection of gastrinoma: who, when, where and why? Eur J Gastroenterol Hepatol 2012;24:368-374.
147.
Giovinazzo F, Butturini G, Monsellato D, et al: Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg 2013;65:19-24.
148.
Norton JA, Harris EJ, Chen Y, et al: Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 2011;146:724-732.
149.
Birnbaum DJ, Turrini O, Vigano L, et al: Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol 2014.
150.
Birnbaum DJ, Turrini O, Ewald J, et al: Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival. Eur J Surg Oncol 2014;40:1564-1571.
151.
Haugvik SP, Labori KJ, Edwin B, et al: Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal 2012;2012:357475.
152.
Haugvik SP, Labori KJ, Waage A, et al: Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors. J Gastrointest Surg 2013;17:1224-1232.
153.
Krampitz GW, Norton JA: Current management of the Zollinger-Ellison syndrome. Adv Surg 2013;47:59-79.
154.
Imamura M, Komoto I, Ota S, et al: Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011;17:1343-1353.
155.
Kulke MH, Anthony LB, Bushnell DL, et al: NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-752.
156.
Peranteau WH, Palladino AA, Bhatti TR, et al: The surgical management of insulinomas in children. J Pediatr Surg 2013;48:2517-2524.
157.
Mehrabi A, Fischer L, Hafezi M, et al: A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014;43:675-686.
158.
Guo Q, Wu Y: Surgical treatment of pancreatic islet cell tumor: report of 44 cases. Hepatogastroenterology 2013;60:2099-2102.
159.
Knigge U, Hansen CP: Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819-831.
160.
Su AP, Ke NW, Zhang Y, et al: Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. J Surg Res 2014;186:126-134.
161.
Sciuto A, Abete R, Reggio S, et al: Laparoscopic spleen-preserving distal pancreatectomy for insulinoma: experience of a single center. Int J Surg 2014;12(suppl 1):S152-S155.
162.
Fernandez-Cruz L, Martinez I, Cesar-Borges G, et al: Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1. J Gastrointest Surg 2005;9:381-388.
163.
Al-Kurd A, Chapchay K, Grozinsky-Glasberg S, et al: Laparoscopic resection of pancreatic neuroendocrine tumors. World J Gastroenterol 2014;20:4908-4916.
164.
Fernandez-Cruz L, Blanco L, Cosa R, et al: Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008;32:904-917.
165.
Haugvik SP, Marangos IP, Rosok BI, et al: Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors. World J Surg 2013;37:582-590.
166.
Cheema A, Weber J, Strosberg JR: Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol 2012;19:2932-2936.
167.
Gaujoux S, Partelli S, Maire F, et al: Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2013;98:4784-4789.
168.
de Mestier L, Gaujoux S, Cros J, et al: Long-term Prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg 2015;262:384-388.
169.
Gaujoux S, Gonen M, Tang L, et al: Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol 2012;19:4270-4277.
170.
Ito T, Jensen RT: Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010;12:448-457.
171.
Luk CP, Parsons R, Lee YP, et al: Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013;47:773-780.
172.
Corleto VD, Festa S, Di Giulio E, et al: Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 2014;21:3-8.
173.
Famularo G, Gasbarrone L, Minisola G: Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 2013;12:709-716.
174.
Reimer C: Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013;27:443-454.
175.
Heidelbaugh JJ, Metz DC, Yang YX: Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 2012;66:582-591.
176.
Vakil N: Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-445.
177.
Ojeaburu JV, Ito T, Crafa P, et al: Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011;56:139-154.
178.
Tabarin A, Goichot B: Treatment: symptomatic treatment of hypoglycaemia. Ann Endocrinol (Paris) 2013;74:196-199.
179.
Baudin E, Caron P, Lombard-Bohas C, et al: Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris) 2013;74:523-533.
180.
Ferrer-Garcia JC, Iranzo Gonzalez-Cruz V, Navas-DeSolis S, et al: Management of malignant insulinoma. Clin Transl Oncol 2013;15:725-731.
181.
Jawiarczyk A, Bolanowski M, Syrycka J, et al: Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review. Exp Clin Endocrinol Diabetes 2012;120:68-72.
182.
Oberg KE, Reubi JC, Kwekkeboom DJ, et al: Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-53, 753.
183.
Bernard V, Lombard-Bohas C, Taquet MC, et al: Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 2013;168:665-674.
184.
Chen J, Wang C, Han J, et al: Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther 2013;13:737-743.
185.
Maiza JC, Vezzosi D, Grunenwald S, et al: Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas. J Endocrinol Invest 2011;34:e253-e258.
186.
de Herder WW, van Schaik E, Kwekkeboom D, et al: New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 2011;75:277-284.
187.
van Schaik E, van Vliet EI, Feelders RA, et al: Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab 2011;96:3381-3389.
188.
Garby L, Caron P, Claustrat F, et al: Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 2012;97:2093-2104.
189.
Ghazi AA, Amirbaigloo A, Dezfooli AA, et al: Ectopic acromegaly due to growth hormone releasing hormone. Endocrine 2013;43:293-302.
190.
Eldor R, Glaser B, Fraenkel M, et al: Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf) 2011;74:593-598.
191.
Baldelli R, Barnabei A, Rizza L, et al: Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne) 2014;5:7.
192.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-185.
193.
Imhof A, Brunner P, Marincek N, et al: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-2423.
194.
Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
195.
Kwekkeboom DJ, Kam BL, Van Essen M, et al: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-R73.
196.
Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652-1659.
197.
Bodei L, Mueller-Brand J, Baum RP, et al: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800-816.
198.
Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009;90:184-189.
199.
Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016;103:119-124.
200.
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for neuroendocrine neoplasm of the jejunum and ileum. Neuroendocrinology 2016;103:125-138.
201.
Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for colorectal neuroendocrine neoplasms (NEN). Neuroendocrinology 2016;103:139-143.
202.
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; all other Vienna Consensus Conference participants: ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016;103:144-152.
203.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants: ENETS consensus guidelines for high grade gastro-entero-pancreatic (GEP) neuroendocrine tumours and neuroendocrine carcinomas (NEC). Neuroendocrinology 2016;103:186-194.
204.
Roberts RE, Zhao M, Whitelaw BC, et al: GLP-1 and Glucagon Secretion from a Pancreatic Neuroendocrine Tumor Causing Diabetes and Hyperinsulinemic Hypoglycemia. J Clin Endocrinol Metab 2012;97:3039-3045.
205.
Todd JF, Stanley SA, Roufosse CA, et al: A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 2003;361:228-230.
206.
Schneider R, Waldmann J, Swaid Z, et al: Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity. Pancreas 2011;40:213-221.
207.
Wang HS, Oh DS, Ohning GV, et al: Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J Mol Neurosci 2007;33:225-231.
208.
Pacak K, Jochmanova I, Prodanov T, et al: New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013;31:1690-1698.
209.
Yu R: Pancreatic alpha-cell hyperplasia: facts and myths. J Clin Endocrinol Metab 2014;99:748-756.
210.
Yu R, Wawrowsky K, Zhou C: A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr 2011;58:258-266.
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
